Jae Park, MD, discusses his key takeaways from chimeric antigen receptor T cells in the treatment landscape of patients with acute lymphoblastic leukemia.
Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses his key takeaways from chimeric antigen receptor (CAR) T cells in the treatment landscape of patients with acute lymphoblastic leukemia (ALL).
The important message is that there is a lot of interest in CAR T-cell therapy in patients with ALL, says Park, and more so than there had been in the past. However, there are rightful concerns regarding the toxicity of these therapies. It is important to think of this when considering administering a CAR T-cell therapy to a patient. It may not be the right therapy to all patients with ALL who relapse, but a lot of factors go into this, Park explains.
It is important to think about using CAR T-cell therapy early in patients with ALL, and they should be consulted early. ALL is a rare disease, so Park strongly encouraged physicians and patients to reach out to cancer centers that administer CAR T cells. For patients who do not have access to clinical trials for CAR T-cell therapy, centers like Memorial Sloan can assist in finding local centers that do have these studies available.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More